IndustryCompany release

Delaware court approves sale of BioXcel Therapeutics' assets to Teva, cancels auction

🇺🇸 BioXcel Therapeutics, Inc. (BTAIQ) · Fri 30 Oct 2026

The US Bankruptcy Court for the District of Delaware has approved the sale of BioXcel's purchased assets to Teva Pharmaceuticals International GmbH, free and clear of liens and claims.

The U.S. Bankruptcy Court for the District of Delaware has entered an order approving the sale of BioXcel Therapeutics' purchased assets to Teva Pharmaceuticals International GmbH. The sale is free and clear of liens and claims. BioXcel announced the order on 30 October 2026.

Teva was the stalking horse bidder under an Asset Purchase Agreement dated 27 August 2026. The court found Teva's bid to be the best one and cancelled the auction. The order is effective immediately.

The order also approves the assignment of certain contracts and leases to the buyer. The information available does not say which contracts or leases are covered.

The text available does not specify which assets or products are included in the sale, nor does it give the purchase price or a closing date. It is therefore unclear from this item how marketing authorisations, clinical programmes or commercial rights will be handled.

As general context, a stalking horse bid is an initial offer set in a bankruptcy sale process. It serves as a floor for any competing bids, and the court can approve the sale without an auction if no better offer is received.

What it means for your team

  • Regulatory teams with dealings with BioXcel should watch for details of which assets and products transfer to Teva, as the order itself does not specify them.
  • Pharmacovigilance and quality teams should check for any later notices on responsibility for safety data, licences and contracts affected by the assignment.
  • Market-access teams should not assume any product supply or pricing changes yet, as no product or commercial details have been disclosed.

Company's press release (SEC filing): BioXcel Therapeutics, Inc. ↗

Article written by VigiEye from the official source (BioXcel Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →